| Basics |
XBiotech Inc. Common Stock
XBiotech Inc is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases.
|
| IPO Date: |
April 13, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$75.61M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.27 | 2.93%
|
| Avg Daily Range (30 D): |
$0.09 | 3.84%
|
| Avg Daily Range (90 D): |
$0.07 | 2.59%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.12M |
| Avg Daily Volume (30 D): |
.12M |
| Avg Daily Volume (90 D): |
.07M |
| Trade Size |
| Avg Trade Size (Sh.): |
120 |
| Avg Trade Size (Sh.) (30 D): |
140 |
| Avg Trade Size (Sh.) (90 D): |
139 |
| Institutional Trades |
| Total Inst.Trades: |
185 |
| Avg Inst. Trade: |
$1.7M |
| Avg Inst. Trade (30 D): |
$1.87M |
| Avg Inst. Trade (90 D): |
$1.87M |
| Avg Inst. Trade Volume: |
.14M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.63M |
| Avg Closing Trade (30 D): |
$4.37M |
| Avg Closing Trade (90 D): |
$4.37M |
| Avg Closing Volume: |
245.72K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.95
|
$-.2
|
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$
|
$ M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -29.16M
|
$ -6.01M
|
$
|
|
Operating Income / Loss
|
$ -34.68M
|
$ -6.05M
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -39.34M
|
$
|
$
|
|
PE Ratio
|
|
|
|
|
|
|
